Drug Profile


Alternative Names: EML 676; IDD 676; lindolrestat; lindorestat

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute for Diabetes Discovery LLC
  • Class Antihyperglycaemics; Indoleacetic acids; Small molecules; Thiazoles
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetic neuropathies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Diabetic-neuropathies in North America (PO)
  • 28 Sep 2005 A preclinical study has been added to the pharmacokinetics and Diabetes pharmacodynamics sections
  • 31 Aug 2005 The Institute for Diabetes Discovery and Alinea Pharmaceuticals have entered into an agreement to co-develop lidorestat for diabetic complications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top